OptimizeRx (OPRX) Stock Price
OptimizeRx Price
OptimizeRx (OPRX) Stock | ISIN US68401U2042 | WKN A2JL4Z. The current OptimizeRx stock price is 5.3 USD (2026). Revenue is 122.84 M USD. Net income is 16.7 M USD. The P/E ratio is 5.81. Market capitalization is 98.79 M USD. OptimizeRx operates in the Health sector.
OptimizeRx stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of OptimizeRx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OptimizeRx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OptimizeRx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | OptimizeRx Price |
|---|
OptimizeRx Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
OptimizeRx Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales OptimizeRx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OptimizeRx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OptimizeRx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares OptimizeRx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OptimizeRx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
OptimizeRx stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
OptimizeRx Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
OptimizeRx business model & stock analysis
OptimizeRx SWOT Analysis
Strengths
OPTIMIZERx Corp has several key strengths that contribute to its success in the market. Firstly, the company offers innovative and leading-edge technology solutions in the healthcare industry, providing a competitive advantage over its competitors. Additionally, OPTIMIZERx Corp has established strong strategic partnerships with hospitals, healthcare providers, and pharmaceutical companies, enabling it to expand its customer base and enhance its product offerings. Furthermore, the company has a dedicated and skilled workforce, fostering a culture of innovation, collaboration, and customer-centricity.
Weaknesses
Despite its strengths, OPTIMIZERx Corp also faces certain weaknesses that can hinder its growth and market position. One notable weakness is the dependence on a limited number of major clients for a significant portion of its revenue. This vulnerability exposes the company to potential risks, such as losing key clients or facing pricing pressures. Moreover, OPTIMIZERx Corp operates in a highly competitive market, where disruptive technologies and emerging companies pose a threat to its market share. The company needs to continuously invest in research and development to stay ahead of the competition.
Opportunities
OPTIMIZERx Corp has identified several opportunities that can drive future growth and profitability. The increasing adoption of digital healthcare solutions presents a promising opportunity for the company to expand its customer base and enhance its product portfolio. Moreover, the growing focus on personalized medicine and patient-centric care provides a platform for OPTIMIZERx Corp to develop tailored and targeted solutions that address specific patient needs. Additionally, the company can explore strategic partnerships with telehealth providers, electronic health record vendors, and other stakeholders in the healthcare ecosystem to leverage synergies and expand its market reach.
Threats
OPTIMIZERx Corp operates in an industry that faces various threats, which can impact its operations and financial performance. One significant threat is the strict regulatory environment in the healthcare sector. Compliance with existing and new regulations can increase the company's operational costs, hinder product development, and slow down market penetration. Additionally, the constantly evolving technology landscape poses a threat, as competitors can develop similar or superior solutions, challenging OPTIMIZERx Corp's market position. Economic downturns and budget constraints in the healthcare industry can also lead to reduced spending on technology solutions, affecting the company's revenue.
OptimizeRx Segments
OptimizeRx Eulerpool Fair Value
OptimizeRx historical P/E ratio, EBIT multiple, and P/S ratio
OptimizeRx annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
OptimizeRx shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
OptimizeRx Earnings Estimates
OptimizeRx Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/12/2026 | 0USD | 18.72 MUSD | 2026 Q1 |
| 5/11/2026 | 0USD | 18.72 MUSD | 2026 Q1 |
| 4/30/2026 | 0USD | 18.72 MUSD | 2026 Q1 |
| 3/5/2026 | 0.23USD | 31.72 MUSD | 2025 Q4 |
| 2/19/2026 | 0.23USD | 31.72 MUSD | 2025 Q4 |
| 11/13/2024 | 0.06USD | 25.5 MUSD | 2024 Q3 |
| 5/8/2024 | -0.07USD | 20.14 MUSD | 2024 Q1 |
| 2/21/2024 | 0.27USD | 26.1 MUSD | 2023 Q4 |
| 8/7/2023 | 0.08USD | 17.29 MUSD | 2023 Q2 |
| 5/2/2023 | 0.04USD | 16.4 MUSD | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the OptimizeRx stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
OptimizeRx shareholder structure
| % | Name |
|---|---|
8.09175% | |
7.4274% | |
5.8684% | |
5.68192% | |
4.24163% | |
3.37407% | |
2.9282% | |
2.84792% | |
2.72223% | |
2.53472% |
OptimizeRx Executives and Management Board
Ms. Marion Odence-Ford
(60)General Legal Officer and Chief Human Resources Officer
Mr. Edward Stelmakh
(59)Chief Financial & Strategic Officer
Mr. Stephen Silvestro
(47)President, Chief Executive Officer, Director · since 2019
Ms. Lynn Vos
(69)Independent Chairperson of the Board
Mr. Patrick Spangler
(69)Independent Director
OptimizeRx Supply Chain
Frequently asked questions about OptimizeRx
Some of the main competitors of OPTIMIZERx Corp in the market include Updox, Allscripts Healthcare Solutions, and NextGen Healthcare.
OptimizeRx stock
OptimizeRx Peer Group
OptimizeRx Ticker
OptimizeRx FIGI
All fundamentals and in-depth analysis of OptimizeRx
Our stock analysis for OptimizeRx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OptimizeRx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.